Contract Research Organization (CRO) Market 2017-2018 and 2022: Outsourcing in Drug Discovery

News provided by

Apr 12, 2018, 09:45 ET

DUBLIN, April 12, 2018 /PRNewswire/ --

The "Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 8th Edition" report has been added to ResearchAndMarkets.com's offering.

What's happening in the drug discovery market? How much are pharma companies outsourcing? What parts of the process are seeing volume by CROS? What's happening in China and Eastern Europe? Which companies are in leadership in the market?

In eight editions, this report has provided answers to these questions and more. As the pharmaceutical industry seeks to boost production recover from a lack of blockbusters, and patients and providers demand effective biotherapies, the race to discover new drugs is more. The research provides information unavailable from any other source, the result of interviews with companies and experts, as well as economic research from the publisher's proprietary database.

This report contains 2017 market size estimates and 2022 forecasts for 21 different parts of the process that might be outsourced.

These include:

Chemistry Services
Building Blocks
Compound Synthesis
Libraries
Process Research
Biology Services
Protein Expression
Structural Analysis
Target Validation
Pathways Analysis
Screening Services
Assay Development
Primary Screening
Secondary Screening
Lead Optimization
Early ADMET
Analogues Creation
Computational Support
Other Services

For each of these categories, market size is provided and forecasts are given to 2022. The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).

Report Coverage

Current outsourcing in drug discovery market size and future forecast
R&D scale-backs at major companies
The fastest-growing services for outsourcers
Logistics, IP, regulatory and other issues in China, India and Eastern Europe
Common discovery outsourcing pitfalls and how companies overcame them
What factors should a client consider when deciding whether to do a project in-house or outsource it?
The choice of a domestic outsourcing partner, or an overseas supplier?
Best practices when working with a CRO
Strategic vs. tactical outsourcing models

Company Profiles

Albany Molecular Research, Inc.
Aptuit, a Division of Evotec AG
Asclepia MedChem Solutions
Asinex Ltd.
AsisChem Inc.
Aurelia Bioscience Ltd
Axxam SpA
BioDuro
Charles River Laboratories, Inc.
Charnwood Molecular
ChemBridge Corp.
Chemical Diversity Inc. (ChemDiv)
ChemPartner Co., Ltd., subsidiary of ShangPharma
Covance Inc. (Laboratory Corporation of America)
CreaGen Biosciences, Inc.
Crown Bioscience
Cyprotex PLC, an Evotec AG Company
Domainex
Enamine Ltd.
Evotec AG
Exelgen Discovery
GVK Biosciences Private Limited (GVK Bio)
GenScript USA Inc.
Graffinity Pharmaceuticals GmbH (subsidiary of NovAliX S.A.S)
HitGen Ltd.
Hutchison MediPharma, Ltd.
Jubilant Biosys Ltd. (JBL), a subsidiary of Jubilant Life Sciences Ltd.
Nanosyn, Inc.
Olon Ricerca Biosciences
Pharmaron, Inc.
Selcia Limited
Sundia MediTech Company, Ltd.
TCG Lifesciences Pvt Ltd.
Viva Biotech, Ltd.
WuXi AppTec Co. Ltd.

Key Topics Covered

1. Executive Summary

2. Introduction to Outsourcing Drug Discovery

3. The Drug Discovery Process

4. Outsourcing Drug Discovery

5. Drug Discovery Outsourcing Market

6. Competitor Profiles

7. Appendix: Company Names and Addresses

For more information about this report visit https://www.researchandmarkets.com/research/d6wlhn/contract_research?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets